Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery
Status:
Terminated
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
This is a study to test the efficacy of using standard immune therapy for melanoma prior to
stereotactic radiosurgery (ipilimumab induction), as compared to stereotactic radiosurgery
followed by immune therapy. The study's hypothesis is that ipilimumab induction is as good as
or better than controlling brain metastases as compared to stereotactic radiosurgery followed
by immune therapy.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center